Algorae Pharmaceuticals Limited

OTCPK:LVCL.F Stock Report

Market Cap: US$8.0m

Algorae Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Algorae Pharmaceuticals's earnings have been declining at an average annual rate of -4.2%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 58% per year.

Key information

-4.2%

Earnings growth rate

21.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-58.0%
Return on equity-69.5%
Net Margin-1,673.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Algorae Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:LVCL.F Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-211
31 Mar 240-211
31 Dec 230-211
30 Sep 230-201
30 Jun 230-201
31 Mar 230-202
31 Dec 220-302
30 Sep 220-202
30 Jun 220-201
31 Mar 220-202
31 Dec 210-202
30 Sep 210-202
30 Jun 210-102
31 Mar 210-102
31 Dec 200-102
30 Sep 200-102
30 Jun 201-102
31 Mar 201-102
31 Dec 191-202
30 Sep 191-303
30 Jun 191-303
31 Mar 191-203
31 Dec 181003
30 Sep 181003
30 Jun 181003
31 Mar 181-204
31 Dec 171-404
30 Sep 171-404
30 Jun 171-404
31 Mar 171-404
31 Dec 161-404
30 Sep 161-304
30 Jun 161-303
31 Mar 161-513
31 Dec 150-622
30 Sep 151-722
30 Jun 151-722
31 Mar 152-721
31 Dec 144-621
30 Sep 146-621
30 Jun 148-720
31 Mar 148-611
31 Dec 139-611

Quality Earnings: LVCL.F is currently unprofitable.

Growing Profit Margin: LVCL.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LVCL.F is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.

Accelerating Growth: Unable to compare LVCL.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LVCL.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).


Return on Equity

High ROE: LVCL.F has a negative Return on Equity (-69.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies